Strong Psychedelic Data In 1H 2021 Sets The Stage For Key Endpoint Results Later This Year Jun 23, 2021
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with… Jun 23, 2021
PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including… Jun 22, 2021
Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies Jun 16, 2021
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression Jun 15, 2021
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic… Jun 15, 2021
Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program Jun 14, 2021
